retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial What GLP‑3 Really Is: Triple‑Receptor Drug Retatrutide, a GIP, GLP-1 and
Description
35-39.9: 0.61, 0.41 to 0.91
01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
For a 250-pound person, the difference between 14% weight loss and 28% weight loss is the difference between losing 35 pounds and losing 70 pounds
The findings have begun to shift the conversation from fear toward reassurance

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torne CW, Ryan DH (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

It is the first triple-agonist peptide to reach Phase 3 clinical trials, activating GLP-1, GIP, and glucagon receptors simultaneously

Journal of Surgical Research
